Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
| Autor: | Aboud, Michael, Kaplan, Richard, Lombaard, Johannes, Zhang, Fujie, Hidalgo, José A, Mamedova, Elmira, Losso, Marcelo H, Chetchotisakd, Ploenchan, Brites, Carlos, Sievers, Jörg *, Brown, Dannae, Hopking, Judy, Underwood, Mark, Nascimento, Maria Claudia, Punekar, Yogesh, Gartland, Martin, Smith, Kimberly |
|---|---|
| Zdroj: | In The Lancet Infectious Diseases March 2019 19(3):253-264 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|